Ticagrelor monotherapy after short duration of dual antiplatelet therapy compared to continued dual antiplatelet therapy in patients with acute coronary syndromes undergoing percutaneous coronary interventions: an updated meta-analysis

被引:0
|
作者
Mansuri, Zeeshan [1 ]
Ashraf, Hadiah [2 ]
Taikadan, Thahsin [3 ]
Rajith, Gokul [4 ]
Ayesha, Ayesha [5 ]
Fatima, Urooj [6 ]
Erzinger, Gabriel [7 ]
机构
[1] GCS Med Coll & Res Ctr, Dept Cardiol, Opp DRM Off,Naroda Rd, Ahmadabad 380025, Gujarat, India
[2] Rawalpindi Med Univ, Rawalpindi, Pakistan
[3] Calicut Med Coll, Kozhikode, India
[4] All India Inst Med Sci, Gauhati, India
[5] Shifa Coll Med, Islamabad, Pakistan
[6] Jinnah Sindh Med Univ, Karachi, Pakistan
[7] Univ Joinville Reg UNIVILLE, Joinville, Brazil
关键词
dual anti-platelet therapy; percutaneous coronary intervention; ticagrelor; ASPIRIN;
D O I
10.1097/MCA.0000000000001417
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background The optimum duration of dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) in patients with acute coronary syndromes (ACS) remains controversial. Ticagrelor monotherapy after short duration of DAPT (1-3 months) is a subject of research. We conducted an updated systematic review and meta-analysis comparing the ticagrelor monotherapy with continued DAPT after short duration of DAPT in patients with ACS undergoing PCI. Methods PubMed, Embase, and Cochrane databases were searched for studies comparing ticagrelor monotherapy to DAPT after PCI and reported the outcomes of major adverse cardiovascular and cerebrovascular events (MACCE); net adverse clinical events (NACE); myocardial infarction (MI); major bleeding; death from any cause; definite or probable stent thrombosis; and target vessel revascularization (TVR). Data were extracted from published reports and quality assessment was performed per Cochrane recommendations. Statistical analysis was performed using Review Manager (Cochrane collaboration). Heterogeneity was examined with I-2 test. Results Of 3,208 results, five studies with 21,407 patients were included of which 50% received ticagrelor monotherapy. Studies had reported follow up of 12 months. Major bleeding [hazard ratio 0.47; 95% confidence interval (CI), 0.37-0.61; P < 0.001], NACE (hazard ratio 0.71; 95% CI, 0.56-0.90; P = 0.005), and all-cause death (hazard ratio 0.76; 95% CI, 0.59-0.98; P = 0.04) were significantly less with ticagrelor monotherapy. Other outcomes were comparable in both groups. Conclusion In patients with ACS undergoing PCI, ticagrelor monotherapy reduces major bleeding, NACE and all-cause death as compared to continued DAPT for 12 months. Major ischemic outcomes were similar. Ticagrelor monotherapy is the way forward after short duration of DAPT after PCI in ACS.
引用
收藏
页码:590 / 597
页数:8
相关论文
共 50 条
  • [31] Genotype-guided antiplatelet therapy compared with standard therapy for patients with acute coronary syndromes or undergoing percutaneous coronary intervention: A systematic review and meta-analysis
    Wang, Xin
    Wang, Shihui
    Yang, Jing
    Yu, Xiaojia
    Liu, Lihong
    THROMBOSIS RESEARCH, 2020, 193 : 130 - 138
  • [32] Duration of dual antiplatelet therapy in acute coronary syndrome
    Wilson, Simon John
    Newby, David E.
    Dawson, Dana
    Irving, John
    Berry, Colin
    HEART, 2017, 103 (08) : 573 - 580
  • [33] Clopidogrel Versus Ticagrelor as Part of Dual-Antiplatelet Therapy for Patients With Acute Coronary Syndrome: A Meta-Analysis
    Myredal, Anna
    Bergh, Niklas
    Sjovall, Henrik
    Wallerstedt, Susanna
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2021, 78 (19) : B193 - B193
  • [34] Ischemic Versus Bleeding Risk Consideration for the Duration of Dual Antiplatelet Therapy in Patients Undergoing Percutaneous Coronary Interventions
    Gajanana, Deepakraj
    Rogers, Toby
    Iantorno, Micaela
    Weintraub, William
    Shlofmitz, Evan
    Khalid, Nauman
    Chen, Yuefeng
    Torguson, Rebecca
    Khan, Jaffar
    Musallam, Anees
    Ben-Dor, Itsik
    Satler, Lowell
    Waksman, Ron
    JACC-CARDIOVASCULAR INTERVENTIONS, 2019, 12 (04) : S10 - S11
  • [35] Duration of dual antiplatelet therapy after coronary stenting
    Briasoulis, Alexandros
    Palla, Mohan
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2016, 222 : 1064 - 1067
  • [36] Dual antiplatelet therapy after acute coronary syndromes: no time for a CHANGE
    Capodanno, Davide
    EUROINTERVENTION, 2017, 13 (10) : 1133 - 1135
  • [37] Prasugrel as Antiplatelet Therapy in Patients With Acute Coronary Syndromes or Undergoing Percutaneous Coronary Intervention
    Fletcher, Barbara
    Thalinger, Karen K.
    CRITICAL CARE NURSE, 2010, 30 (05) : 45 - 54
  • [38] Dual Antiplatelet Therapy Dilemmas: Duration and Choice of Antiplatelets in Acute Coronary Syndromes
    Matthew Tomey
    Roxana Mehran
    Current Cardiology Reports, 2013, 15
  • [39] Duration of Dual Antiplatelet Therapy After Coronary Stenting
    Siasos, Gerasimos
    Mourouzis, Konstantinos
    Oikonomou, Evangelos
    Vavuranakis, Manolis
    Vogiatzi, Georgia
    Briasoulis, Alexandros
    Papageorgiou, Nikolaos
    Papaioannou, Theodore G.
    Zografos, Thodoris
    Papapanagiotou, Angeliki
    Papavassiliou, Athanasios G.
    Stefanadis, Christodoulos
    Tousoulis, Dimitris
    CURRENT PHARMACEUTICAL DESIGN, 2016, 22 (29) : 4583 - 4595
  • [40] Dual Antiplatelet Therapy Dilemmas: Duration and Choice of Antiplatelets in Acute Coronary Syndromes
    Tomey, Matthew
    Mehran, Roxana
    CURRENT CARDIOLOGY REPORTS, 2013, 15 (10)